The aim of this study was to determine whether the level of HER-2 gene amplification using FISH assays significantly influenced recurrence-free survival (RFS) and overall survival (OS) in non-metastatic breast cancer treated with trastuzumab-based neoadjuvant therapy. Here, ERBB2 is linked to breast carcinoma.